Schering Corp is recalling 587 units of Trilafon Injection, USP (perphenazine) 5 mg/1 mL ampules because of a lack of assurance of sterility. This prescription medication is used as an antipsychotic, and the recall affects product sold through direct accounts, Pharmacia, and Serono Laboratories. While no incidents or injuries have been reported to date, the lack of sterility in an injectable product can lead to serious health complications for patients.
A lack of sterility in an injectable drug means the product may be contaminated with microorganisms. Injecting a non-sterile medication directly into the body can cause severe infections, abscesses, or life-threatening systemic illness.
Contact healthcare provider and return for refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.